Using this model, the rates of serious infection for the 3 anti-TNFα drugs were 61.7 per 1,000 person-years for etanercept, 68.9 per 1,000 person-years for infliximab, and 54.2 per 1,000 person-years for adalimumab (Table 2). Here, TNF is linked to infection.